Abstract
There is growing interest in the use of bone marrow-derived stem cells to treat a variety of acute and chronic conditions, including cardiovascular and orthopedic indications. The SynGenX™-2000 system is a novel point of care device for efficient and reproducible preparation of bone marrow concentrate (BMC) from bone marrow aspirate (BMA). The objective of this study was to characterize the cell counts of BMA from normal healthy donors and of BMC following processing with the SynGenX™-2000 using complete blood counts (CBC) and flow cytometer-based analysis, and to determine the viability of the CD34+ cells in the BMC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
